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Background and Objectives. Our aim was to identi-
fy risk factors in adults with diffuse large cell lym-
phoma (DLCL) at first relapse.
Design and Methods. We studied 474 patients
observed at 45 centers in Italy. The median time
from diagnosis to relapse was 395 days, the medi-
an age at relapse was 55 years and the median fol-
low-up from relapse was 3.3 years. Salvage thera-
py consisted of polychemotherapy in 79% of
patients, monochemotherapy and/or radiotherapy
and/or surgery alone in 16%, and palliative thera-
py in 5%. Salvage treatment was intensified with
high-dose chemotherapy + stem cell transplant in
20% of patients. Overall survival (OS) and pro-
gression-free survival (PFS) were compared by sex,
International Prognostic Index at diagnosis, histol-
ogy, B/T phenotype, initial treatment, salvage ther-
apy, and features at relapse: time from diagnosis,
lactate dehydrogenase (LDH), stage, performance
status and bone marrow involvement. Cox models,
adjusted for salvage therapy, were performed with
factors related to overall survival and progression-
free survival.
Results. Overall response (complete + partial) was
63%, OS at 3 years 35% and PFS at 3 years 26%.
Relapse within 12 months from diagnosis, elevated
serum LDH, advanced stage and poor performance
status were independent adverse factors for OS and
PFS. The cumulative number of adverse factors is
proposed as a prognostic index for DLCL at first
relapse since it identifies risk groups (p<0.0001)
and has been validated (p=0.01). Moreover, it pre-
dicts OS and PFS in the selected group of patients
with a responsive relapse (p<0.0001).
Asignificant proportion of patients with his-tologically aggressive non-Hodgkin’s lym-phoma relapse after achieving a complete
response (CR) with combination chemotherapy.1-6
Different salvage chemotherapy regimens induce
CR or partial response (PR) in more than 50% of
such patients7-12 and those with sensitive relapses
benefit from adjuvant high-dose therapy (HDT)
with autologous stem cell transplant (SCT).13 How-
ever, it appears that a worse prognosis is associat-
ed with an early relapse or with any of the fol-
lowing features at relapse: poor performance sta-
tus, large tumor mass, high lactate dehydrogenase
(LDH) levels, more than 3 nodal sites or an
advanced Ann Arbor stage.8,14-18 More recently, the
age-adjusted International Prognostic Index (IPI)19
at relapse was associated with both overall survival
(OS) and progression-free survival (PFS) and its
prognostic value was independent from time to
relapse.20-21 These results must be validated on oth-
er series, since they were achieved either in single
institutions8,14,16,18 or in the selected group of adults
aged less than 60 years who were enrolled in the
PARMA trial.17,20,21 Moreover, while the majority of
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Interpretation and Conclusions. Delay from initial 
diagnosis, LDH, stage and performance status at
relapse should be balanced in comparative studies
of salvage therapy of adults with DLCL. Patients with
more than 2 adverse factors account for one third
of all cases and deserve more effective salvage
treatments. 
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patients included in the PARMA trial had histolog-
ic types which for clinical purposes are grouped as
diffuse large cell lymphoma (DLCL), a significant
number had histologic types (ie. lymphoblastic
lymphoma, diffuse small non-cleaved cell lym-
phoma, follicular large cell lymphoma and diffuse
small-cleaved cell lymphoma) with clinical behav-
iors different from that of DLCL.22-25
Therefore, in Italy, we analyzed prognostic factors
for OS and PFS after first relapse in 474 patients
with DLCL selected from a large cohort of patients
enrolled in prospective trials of initial therapy with
an anthracycline-containing combination chemo-
therapy regimen. 
Design and Methods
Patients
Between January 1987 and April 1997, 1,775
patients aged 13-81 years (median age 50 years)
were initially treated with an anthracycline-includ-
ing combination chemotherapy regimen for DLCL
(patients with lymphoblastic lymphoma or Burkit-
t’s lymphoma or with HIV infection were excluded)
at 41 Italian centers participating in clinical trials.
Many of the patients have been previously
described in reports of initial treatment.29-37 Over-
all, 1,247 patients (70%) achieved a CR and, as of
June 1998, 494 of them (40%) had relapsed. The
first relapse occurred in May 1988, the last in April
1998.
Information on pathologic and clinical features
of the disease at time of first diagnosis, date of
first relapse and survival status at last follow-up
were prospectically registered at each participat-
ing center. The information on some selected fea-
tures of the disease at relapse, modality of salvage
therapy and results of such treatments were
obtained retrospectively. Questionnaires were sent
to participating centers in June 1998 and as of
December 1998 they had been collected for a total
of 474 patients. Therefore, 96% of relapsed
patients could be evaluated. The median follow-
up time from first relapse was 38 months.
Statistics
Potential prognostic factors were scored as fol-
lows: sex (male vs female), age at relapse (<65
years vs ≥65 years), histologic grade according to
the Working Formulation (WF) for clinical usage21
(intermediate grade vs high grade), histologic type
according to the Revised European American Lym-
phoma (REAL) classification22 (diffuse large B-cell
vs peripheral T-cell vs anaplastic large-cell), tumor
immunophenotype (B vs T), IPI at diagnosis (<3 vs
>3), initial chemotherapy regimen (weekly vs oth-
ers), time to relapse (<12 months from initial diag-
nosis vs ≥12 months), Ann Arbor stage at relapse
(I-II vs III-IV), LDH levels at relapse (normal vs ele-
vated), World Health Organization (WHO) perfor-
mance status at relapse (0-1 vs >1), bone marrow
involvement at relapse (yes vs no), therapy at
relapse (chemotherapy and/or radiotherapy and/or
surgery alone vs palliative therapy), intensity of
therapy at relapse (polychemotherapy ± radiother-
apy vs single drug chemotherapy and/or radiother-
apy and/or surgery alone), and polychemotherapy
regimen at relapse (salvage regimen vs 1st or 3rd
generation regimen). The association between vari-
ables was analyzed by the chi-squared test, with
the appropriate degrees of freedom. All tests were
two-sided, and a p value of less than 0.05 was con-
sidered to indicate statistical significance. Actuar-
ial probabilities at 3 years are reported throughout,
if not otherwise specified.
OS was calculated from date of relapse to death
or to last follow-up and PFS from date of relapse to
the first evidence of progressive disease, relapse or
to the last follow-up. Actuarial curves were com-
puted according to the Kaplan and Meier method26
and compared by the two-sided log rank test.27
Patients for whom all of the variables potentially
having prognostic value were assessed constituted
the group in which a Cox proportional-hazards
model according to a backward selection was con-
structed to detect independent predictors of OS and
PFS.28 Validation of criteria for the definition of risk
after relapse were performed by log-rank on
patients, selected from among those excluded from
the previous group, for whom, however, all of the
variables contributing to the Cox models had been
assessed. The prognostic value of independent fac-
tors and of therapy at relapse was also evaluated in
the whole population and in treatment subgroups. 
Results
Salvage therapy and outcome
Three hundred and seventy-three patients (79%)
were treated at relapse with combination
chemotherapy (associated with radiotherapy in 59
cases): their median age at time of relapse was 58
years (16-85) with 17% of them older than 65 years.
Their overall response rate was 66% (157 CR, 91 PR),
OS and PFS were 0.35 and 0.25, respectively. Various
regimens were employed at relapse: a 1st or 3rd gen-
eration regimen in 93 patients, a salvage regimen in
216 patients. Salvage regimens consisted of dexam-
ethasone+cytarabine+cisplatin (DHAP) in 55
patients, ifosphamide+etoposide based regimen in
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56, mitoxantrone±etoposide±cytarabine based reg-
imen in 64, and other combinations in 41. No sig-
nificant differences were recorded in the outcome
according to the type of combination chemother-
apy. Seventy-eight patients (16%) received less
intensive treatments (single agent chemotherapy in
34, single agent chemotherapy with radiotherapy
in 7, radiotherapy alone in 32 and surgery alone in
5). The median age of these patients at time of
relapse was 64 years (20-83) with 60% of them
being older than 65 years. Their response-rate was
63% (23 CR, 24 PR), OS and PFS were 0.39 and
0.26, respectively.
Another 23 cases (5%), with a median age of 67
years, received only palliative therapy. None of
them responded, OS was 0.09, and PFS at 2 years
was 0.04. In 95 patients salvage treatment was
intensified by HDT and SCT (91 autologous, 3 allo-
geneic from an HLA-identical sibling and 1 syn-
geneic). The median age of these patients at time
of relapse was 43 years (range 16-66). Eighty-sev-
en patients were in CR or PR at time of intensifi-
cation, 4 were stable, 3 had progressive disease and
1 was not evaluated (Table 1).
So far, 162 responders (94 CRs and 68 PRs) have
relapsed or progressed at a median time of 9
months (range 2-118 months): 92% within 3 years
of relapse. Overall, 309 patients have died and 165
are alive. Among responders, 61 CRs died after
relapse, 60 PRs died after disease progression and
17 (9 CRs and 8 PRs) died without disease relapse
or progression. OS and PFS in all patients were 0.35
and 0.26, respectively, but the majority are expect-
ed to die or to have treatment failure within 2 years
of the relapse (Figure 1). OS and PFS in patients
intensified with HDT and SCT were 0.52 and 0.41,
respectively (not shown).
Prognostic factors for overall survival and
progression-free survival
The univariate analysis is summarized in Table 2.
The patients’ sex and age at relapse did not signif-
icantly influence OS and PFS. According to the
WF,21 patients with high-grade histology had a sig-
nificantly worse OS and PFS than patients with
intermediate-grade lymphoma. By contrast, the
histologic group of the REAL classification22 and
tumor immunophenotype had no significant prog-
nostic value for OS and PFS. IPI at diagnosis was
correlated with OS and PFS: patients scoring ≥3
had a worse outcome after relapse than those scor-
ing <3. Initial chemotherapy regimens, classified
as weekly vs others, had no prognostic value after
relapse: the 2 groups were comparable both for
age at relapse (median age was 55 years in both
groups) and overall response to salvage therapy
(59% in those receiving a weekly regimen vs 64%
in the others, p = n.s.). In our study, the strong pre-
dictive value of time to relapse is confirmed:
patients who relapse within 12 months from the
initial diagnosis have a significantly shorter OS and
PFS than those relapsing later. Half of the patients
Risk factors in relapsed diffuse large cell lymphoma
Figure 1. Actuarial overall survival (OS) and progression-
free survival (PFS) from first relapse in 474 patients with 
diffuse large cell lymphoma.
Table 1. Therapy at relapse and outcome.
Patients RR* OS° PFS°
Salvage therapy
Combination chemotherapy±RT 373 66% 35±2 25±2
1st or 3rd generation regimen 93 70% 35±5 23±4
Salvage regimen 216 68% 36±3 26±3
DHAP 55 66% 30±6 19±5
IFO+ETO based 56 75% 42±7 28±6
Mito±ETO±CYTA 64 63% 28±6 23±5
Other 41 68% 44±8 36±7
Unknown regimen 64 56% 32±6 27±6
Monochemotherapy and/or RT 78 63% 39±6 26±5
and/or surgery alone
Palliative 23 0% 9±6 4±4#
Total 474 63% 35±2 26±3
Abbreviations: RR, response rate; OS, overall survival; PFS, progression-free 
survival; CR complete response; PR, partial response; RT, radiotherapy; 
DHAP, dexamethasone+cytarabine+cisplatin.8 IFO, ifosfmide; ETO, etoposide;
Mito, mitoxantrone; CYTA, cytarabine; *complete or partial response; 
°actuarial% at 3 years±standard error; #actuarial% at 2 years±standard error.
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with an early relapse died within 7 months and
only 22% of them are expected to be alive at 3
years. In contrast, the median OS of patients
relapsing later is 2 years with a 46% projection at
3 years. We found that other factors at relapse (ie.
Ann Arbor stage, LDH serum levels and perfor-
mance status) had statistically significant effects
on OS and on PFS in the univariate analysis. Bone
marrow involvement at relapse was related to
shorter OS and PFS than in patients without such
a feature, but the difference was not statistically
significant. Multivariate analysis of prognostic fac-
tors for OS and PFS was performed on 283 of our
patients (60%) in whom all of the following vari-
ables were assessed: WF histology, IPI score at
diagnosis, time to relapse, stage at relapse, LDH at
relapse and PS at relapse. Their OS and PFS were
comparable to the OS and PFS of the other 191
patients excluded because of missing variables.
Time to relapse, LDH serum levels, performance
status and Ann Arbor stage contributed to the Cox
models for OS and PFS (Table 3A). Histology and IPI
C. Guglielmi et al.
Figure 2. Actuarial curves from first relapse in 346 patients
with diffuse large cell lymphoma according to the risk 
category as predicted by 4 variables at relapse (time from
diagnosis, LDH levels, Ann Arbor stage and WHO perfor-
mance status): score 4 means time from diagnosis <12
months, LDH above upper normal level, stage III-IV and per-
formance status >1; score 3, 2, 1 and 0 mean 3, 2, 1 and
0 of the bad prognostic variables, respectively. A, overall
survival; B, progression-free survival.
Figure 3. Actuarial curves from first relapse in 252 evaluable
patients with a sensitive relapse of diffuse large cell 
lymphoma according to the risk category as predicted by 4
variables at relapse (time from diagnosis, LDH levels, Ann
Arbor stage and WHO performance status): score 4 means
time from diagnosis <12 months, LDH above upper normal
level, stage III-IV and performance status >1; score 3, 2, 1
and 0 mean 3, 2, 1 and 0 of the bad prognostic variables,
respectively. A, overall survival; B, progression-free survival.
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at diagnosis were not independent prognostic fac-
tors in these models. The prognostic value of the 4
independent prognostic factors and of therapy at
relapse was also evaluated in the whole population
and in treatment subgroups. Giving palliative ther-
apy at relapse was a poor prognostic factor for OS
and PFS (Table 3B). In contrast, OS and PFS were
not significantly influenced by intensity of thera-
py at relapse (Table 3C) or by polychemotherapy
regimen at relapse (Table 3D). Relative risks asso-
ciated with each of the four prognostic variables
(time to relapse, disease stage, LDH serum levels,
and performance status) in models including the
kind of therapy at relapse (Table 3B, C, and D) are
comparable to those in the model not taking into
account therapy at relapse (Table 3A).
Prognostic index for patients at first
relapse
After our prognostic analysis, we attempted to
generate a new prognostic index for patients with
DLCL at first relapse with 4 non-exclusive binary
variables: time from diagnosis to relapse (0, ≥12
months; 1, <12 months), LDH at relapse (0, below
upper normal level; 1, above upper normal level),
Ann Arbor stage at relapse (0, I-II; 1, III-IV) and
WHO performance status at relapse (0, 0-1; 1, >1).
The 4 independent prognostic factors were all
assessed in a total of 346 patients: 283 in the Cox
model and 63 previously excluded from the Cox
model not having been assessed for WF histology
and/or IPI at diagnosis. The sum score predicts OS
and PFS both in the former (p<0.0001) and in the
latter group (p=0.01), thereby validating this prog-
nostic index. Eleven percent of our 346 evaluable
patients scored 0 with this new index, 29% scored
1, 27% scored 2, 21% scored 3 and 12% scored 4.
These groups had comparable median age at
relapse, ranging from 56 years in those scoring 0 to
50 years in those scoring 4. Moreover the mean
score was 1.94 both in the 67 evaluable patients
older than 65 years at relapse and in the 279
younger evaluable patients. The new index dis-
criminates distinct prognostic groups: the proba-
bility of OS was 0.62, 0.52, 0.38, 0.11, and 0.05 in
patients scoring 0, 1, 2, 3 and 4, respectively
(p<0.0001)(Figure 2A). The median OS was 4, 6, 21,
42 months and >7 years in patients scoring 4, 3, 2,
1 and 0, respectively. PFS ranged from 0.54 in score
0 patients to 0.03 in score 4 ones (p<0.0001)(Fig-
ure 2B). Overall response rate to salvage therapy
was strongly correlated to this new prognostic
index,  ranging from 81% in patients scoring 0 to
29% in those scoring 4 (p<0.0001). We, therefore,
Risk factors in relapsed diffuse large cell lymphoma
Table 2. Features of 474 patients and outcome after first
relapse.
Features No. OS1 p PFS1 p
Sex
Female 218 34±2.4 >0.10 28±2.5 >0.10
Male 256 35±2.2 24±2.4
Age (years)2
<65 353 36±2.7 0.22 27±2.5 >0.10
≥65 121 31±4.6 22±4.3
Histology by WF
Intermediate-grade 216 39±3.5 0.01 30±3.3 <0.01
High-grade 207
Histology by REAL
Diffuse large B-cell 294 33±2.2 >0.10 26±2.6 >0.10
Peripheral T-cell 68 38±5.1 24±2.9
Anaplastic large cell 31 34±5.3 15±4.0
Immunophenotype
B 311 34±3.2 >0.10 26±2.5 >0.10
T 74 38±5.8 24±3.1
IPI at diagnosis
<3 294 40±3.0 <0.01 30±2.8 <0.01
=3 130 24±4.0 16±3.5
Initial chemotherapy regimen
Weekly 217 31±2.2 >0.10 23±2.3 >0.10
Others 257 38±3.2 28±2.8
Time to relapse3
=12 months 259 46±3.3 <0.01 32±3.2 <0.01
<12 months 215 27±2.7 18±2.7
Ann Arbor stage2
I-II 158 51±4.3 <0.01 35±4.2 <0.01
=III-IV 310 27±2.7 21±2.4
LDH2
Normal 195 48±3.9 <0.01 38±3.7 <0.01
Elevated 161 18±3.2 10±2.6
WHO performance status2
0-1 263 47±3.3 <0.01 35±3.2 <0.01
>1 194 19±3.0 14±2.6
Bone marrow involvement2
No 289 42±2.7 >0.10 32±2.5 >0.10
Yes 89 33±4.9 20±2.9
Total 474 35±2.4 26±2.6
Abbreviations: OS, overall survival; PFS, progression-free survival; WF, Working
Formulation;22 REAL, revised European American classification of lymphoid 
malignancies;23 IPI, International Prognostic Index;19 LDH, lactate dehydrogenase;
WHO, World Health Organization.1actuarial % at 3 years±standard error; 2at time
of first relapse; 3interval from the initial diagnosis to the first relapse.
also calculated actuarial curves by this index in
252 patients with a sensitive relapse: OS probabil-
ity was 0.72, 0.67, 0.52, 0.18, and 0.14 in patients
scoring 1, 2, 3 and 4, respectively (p<0.0001, Fig-
ure 3A). PFS ranged from 0.66 in score 0 patients
to 0.07 in score 4 ones (p=0.0021)(Figure 3B).
Intensification with HDT and SCT was performed in
20% of responders scoring 0, 33% scoring 1, 31%
scoring 2, 32% scoring 3, and 42% scoring 4 
(p = n.s.). The probability of OS ranged from 0.71 in
score 0 patients to 0.14 in score 4 patients
(p=0.0008) in those with responsive relapses who
were given intensified treatment with HDT and SCT
(not shown). PFS ranged from 0.58 in score 0 to
0.00 in score 4 (p=0.0065), in the same group of
patients (not shown).
Discussion
So far, this is the first retrospective multicenter
prognostic study in an unselected group of adults
with DLCL at first relapse. With the aim of identi-
fying the more relevant prognostic features in
patients with DLCL at first relapse, we wished to
minimize any patient selection which may have
influenced the results of previous prognostic stud-
ies in relapsed aggressive NHL.8,14-18,20-21We, there-
fore, included the great majority of relapses
observed in a large cohort of patients who achieved
CR in prospective trials of initial treatment with
an anthracycline-including regimen at 41 Italian 
centers.
Most of our patients received an effective sal-
vage therapy. In fact, including all cases, 62%
achieved a complete or a partial response and 35%
are expected to survive 3 years after their first
relapse. These results, obtained without any patient
selection, are certainly comparable to those achieved
with the more effective salvage chemotherapy regi-
mens, showing that this series is appropriate for an
analysis of prognostic factors.7-12 In our series, which
includes mainly relapses observed before 1995, the
outcome was not significantly correlated to a spe-
cific salvage regimen and only a minority of
patients with responsive relapse received intensi-
fied treatment by HDT and autologous SCT in
agreement with the indications of the PARMA
study.13 Unfortunately, the intention to intensify
treatment with transplant after response to sal-
vage therapy was not known in our retrospective
study. Therefore, intensification with transplant
was not included in our prognostic analysis. Despite
the limitations of this analysis, ie.  treatment at
initial diagnosis and at relapse not being uniform,
it confirms the previous information that patients
with DLCL at first relapse may have quite different
outcomes depending on time from diagnosis to
relapse, LDH at relapse, Ann Arbor stage at relapse,
and performance status at relapse.16,17,19 These four
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Table 3. Multiple regression analysis of prognostic factors
after relapse (Cox model).
A. All patients are analyzed without therapy at relapse being included into the
model.
Overall survival Progression-free survival
Factor RR CI95 p RR CI95 p
Time from diagnosis to relapsea 1.6 1.2-2.1 <0.01 1.5 1.1-1.9 <0.01
Ann Arbor stage at relapseb 1.5 1.0-2.0 =0.03 1.3 1.0-1.8 =0.04
LDH level at relapsec 1.9 1.4-2.5 <0.01 1.7 1.3-2.3 <0.01
WHO performance status 2.3 1.7-3.2 <0.01 2.0 1.5-2.7 <0.01
at relapsed
B. All patients are analyzed and therapy at relapse is introduced into the model.
Overall survival Progression-free survival
Factor RR CI95 p RR CI95 p
Time from diagnosis to relapse1 1.8 1.4-2.4 <0.01 1.6 1.2-2.0 <0.01
Ann Arbor stage at relapse2 1.4 1.1-1.9 =0.02 1.2 0.9-1.5 =0.09
LDH level at relapse3 1.7 1.3-2.2 <0.01 1.7 1.3-2.2 <0.01
WHO performance status 1.9 1.5-2.5 <0.01 1.8 1.4-2.4 <0.01
at relapse4
Therapy at relapse5 4.4 2.2-9.1 <0.01 4.4 2.2-8.7 <0.01
C. All patients but those given palliative therapy at relapse are analyzed and 
intensity of therapy at relapse is introduced into the model.
Overall survival Progression-free survival
Factor RR CI950 p RR CI950 p
Time from diagnosis to relapse1 1.9 1.4-2.4 <0.01 1.6 1.3-2.0 <0.01
Ann Arbor stage at relapse2 1.5 1.1-2.0 <0.01 1.2 0.9-1.6 =0.12
LDH level at relapse3 1.7 1.3-2.2 <0.01 1.7 1.3-2.2 <0.01
WHO performance status 1.9 1.5-2.5 <0.01 1.8 1.4-2.4 <0.01
at relapse4
Intensity of therapy at relapse6 1.3 0.9-1.8 =0.18 1.1 0.8-1.6 =0.42
D. Patients given polychemotherapy ± radiotherapy at relapse are analyzed and
polychemotherapy regimen at relapse is included into the model.
Overall survival Progression-free survival
Factor RR CI95 p RR CI95 p
Time from diagnosis to relapse1 1.7 1.3-2.3 <0.01 1.5 1.2-2.1 <0.01
Ann Arbor stage at relapse2 1.7 1.2-2.4 <0.01 1.2 0.9-1.6 =0.21
LDH level at relapse3 1.8 1.3-2.4 <0.01 1.7 1.3-2.3 <0.01
WHO performance status 2.2 1.6-3.0 <0.01 2.2 1.6-2.9 <0.01
at relapse4
Polychemotherapy regimen 1.1 0.8-1.6 =0.41 1.1 0.8-1.5 =0.42
at relapse7
Abbreviations: RR, risk ratio; CI95, 95% confidence interval; LDH, lactate 
dehydrogenase; WHO, World Health Organization. 1coded 0 = ≥12 months; 1= <12
month; 2coded 0 = I-II; 1= III-IV; 3coded 0 = normal; 1= increased; 4coded 0 = 0-
1; 1= >1; 5coded 0 = chemotherapy and/or radiotherapy and/or surgery alone;
1=palliative therapy; 6coded 0 = polychemotherapy ± radiotherapy; 1 = single drug
chemotherapy and/or radiotherapy and/or surgery alone; 7coded 0 = salvage 
regimen; 1= 1st or 3rd generation regimen.
factors retain a prognostic value independently of
therapy given to patients at first relapse. A risk
index, based on the number of adverse factors pre-
sent at the time of the first relapse, has been devel-
oped and validated. It is relevant that this risk index
not only correlates with response to salvage ther-
apy, but that it also predicts OS and PFS in the
selected group of patients with sensitive relapses.
Patients with 3 or 4 risk factors, representing 33%
of all cases and 22% of those with a sensitive
relapses, have a dismal outcome and therefore may
enter prospective trials of new treatment strate-
gies. Our additional observation that with this
index we may identify risk groups in sensitive
relapses intensified with transplant confirms a sug-
gestion deriving from the prognostic analysis of
time to relapse and age-adjusted IPI at relapse in
the PARMA study, but this should be validated by
larger studies.21
Surprisingly, the patient’s age at relapse has no
prognostic relevance to OS and PFS. This deserves
consideration since no age restriction was applied
in most trials from which we derived the relapsed
cases. We also included relapses observed in 2
treatment trials designed for patients older than 60
years29-32 and this should compensate some age
restriction adopted in a few other trials. We suspect
that the relatively low proportion of younger adults
who received intensified treatment after response
may obscure a prognostic value of age at relapse
in our series. It is possible that age at relapse will
have prognostic value when most younger respon-
ders are given intensified treatment. Elderly
patients, ie. those older than 65 years at relapse,
represented a significant proportion of our relapsed
cases and deserve specifically designed prospec-
tive trials of salvage therapies.
Another result of this study is the lack of a nega-
tive prognostic value of T-cell immunophenotype as
compared to the B-cell variant in a large series of
DLCL, confirming a previous observation in patients
of the PARMA trial.17 Moreover, as in the PARMA tri-
al,17 the distinction of DLCL into intermediate-grade
or high-grade according to the WF is not an inde-
pendent prognostic factor. Finally, the more recent-
ly proposed REAL classification has no prognostic rel-
evance in our relapsed patients. Therefore, we believe
that other biological aspects of the diseases that we
encompassed in the DLCL group, may reveal features
with prognostic relevance for patients at first relapse.
Mutation of p53,38 tumor proliferative index,39-41
over-expression of bcl-242-48 and CD44 antigen
expression49 have been associated with clinical out-
come in patients with DLCL at diagnosis. Mutation of
p53 and low tumor proliferation, but not bcl-2
expression, are associated with clinical drug resis-
tance in relapsed/refractory non-Hodgkin’s lym-
phoma of various histologies.50 Further studies may
define the prognostic value of such biological fea-
tures of the disease in patients with DLCL at first
relapse. Only a minority of our cases were re-biop-
sied at the time of the first relapse; we, therefore,
included in the prognostic study the pathologic fea-
tures of the disease, ie. histological classification and
tumor immunophenotype, as prospectically defined
at diagnosis. The emergence of a histologically dif-
ferent and sometimes less aggressive variant of the
disease at relapse can be observed in DLCL particu-
larly among late relapses.16,51-55 This may partially
account for the prognostic value of time to relapse
and suggests that the prognostic value of histologic
shift should also be explored.
In conclusion, patients with DLCL at different risks
may be easily identified at the time of the first relapse
by an index calculated from time to relapse, LDH lev-
els, stage and performance status. We propose uti-
lizing this index to stratify patients with DLCL at first
relapse in prospective comparative trials of salvage
therapy. We acknowledge that a more extensive val-
idation of this index may be necessary also in other
countries, and particularly on series in which a high-
er proportion of patients with sensitive relapse are
given intensified treatment with HDT and autologous
SCT.
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Appendix
List of participating centers in alphabetical order
(city, institution, responsible for this study).
1) Avellino, Divisione di Ematologia, Fioravante
Ronconi; 2) Bari, Cattedra e Servizio Autonomo di
Ematologia, Università degli Studi, Enzo Pavone; 3)
Bari, Dipartimento di Scienze Biomediche, Sezione
di Medicina Interna e Oncologia Clinica, Università
degli Studi, Vito M. Lauta; 4) Bari, Unità Operativa
di Medicina, Istituto Oncologico, Giuseppe Colucci;
5) Bologna, Istituto di Ematologia e Oncologia Med-
ica “Lorenzo e Ariosto Seràgnoli”, Pierluigi Zinzani,
Massimo Magagnoli; 6) Bolzano, Ematologia,
Ospedale Generale e Regionale, Paolo Coser; 7)
Cagliari, Divisione di Ematologia, Ospedale Onco-
logico A. Businco, G. Luxi; 8) Cuneo, Divisione di
Ematologia, Az. Ospedaliera S. Croce e Carle, A. Gal-
lamini; 9) Firenze, Cattedra e Divisione di Ematolo-
gia, Università, Giampiero Bellesi; 10) Genova, Cat-
tedra di Ematologia, Marco Gobbi; 11) Genova, DIMI
A.M. Gatti, V. Secondo; 12) Genova, Divisione di
Ematologia 1, Ospedale S.Martino, Gino Santini; 13)
L’Aquila-Teramo, Clinica Medica, Università, Den-
nis Quaglino; 14) Melegnano (MI), Divisione di Med-
icina I e II , Ospedale di Circolo, Gian Piero Benetti;
15) Messina, Istituto di Clinica Oncologica, Univer-
sità, Vincenzo Pitini; 16) Milano, Servizio di Ema-
tologia, Centro “ G. Marcora”, IRCCS Ospedale Mag-
giore, Anna Teresa Maiolo; 17) Modena, Medicina
Interna, Oncologia ed Ematologia, Università, Vit-
torio Silingardi; 18) Napoli, Cattedra di Ematologia,
Università Federico II, Amalia De Renzo; 19) Novara,
Divisione di Medicina, Ospedale Maggiore, M.C.
Bertoncelli; 20) Palermo, Cattedra e Divisione di
Ematologia con T.M.O., Università, Guglielmo Mar-
iani; 21) Pavia, Istituto di Ematologia, Policlinico S.
Matteo, E. Brusamolino; 22) Pavia, Medicina Inter-
na ed Oncologia Medica, IRCCS Policlinico “S. Mat-
teo”, Edoardo Ascari; 23) Perugia, Istituto di Medi-
cina Interna e Scienze Oncologiche, Policlinico
Monteluce, Marina Liberati; 24) Pescara, Diparti-
mento di Ematologia ed Oncologia, USL, Marco
Lombardo; 25) Piacenza, Divisione di Medicina I,
Sezione di Ematologia, Ospedale Civile, Luigi Cavan-
na; 26) Pisa, Dipartimento di Oncologia, Divisione
di Ematologia, Az. Ospedaliera Pisana, Mario Petri-
ni; 27) Potenza, Divisione di Ematologia, Ospedale
S.Carlo, Michele Pizzuti; 28) Reggio Calabria, Divi-
sione di Ematologia, Presidio Ospedali Riuniti “V.G.
Melacrino”, Maura Brugiatelli; 29) Reggio Emilia,
Divisione di Ematologia, Azienda Ospedaliera “S.
Maria Nuova”, Luigi Gugliotta; 30) Roma, Cattedra
di Ematologia, Università Cattolica Sacro Cuore,
Sergio Storti; 31) Roma, Dipartimento di Biotec-
nologie Cellulari ed Ematologia, Università “La
Sapienza”, Maurizio Martelli; 32) San Giovanni
Rotondo (FG), Divisione di Ematologia, IRCCS “Casa
Sollievo della Sofferenza”, Mario Carotenuto; 33)
Siena, Divisione di Ematologia, Monica Bocchia; 34)
Torino, Ematologia Ospedaliera San Giovanni Bat-
tista, Umberto Vitolo, Patrizia Pregno; 35) Torino,
Divisione Universitaria di Ematologia, Ospedale Le
Molinette, Corrado Tarella, Francesco Zallio; 36)
Torino, Oncologia Medica, Ospedale Mauriziano, D.
Rota Scalabrini; 37) Trento, Divisione di Medicina
II, Gino Zambaldi; 38) Udine, Clinica Ematologica,
Policlinico Universitario, Francesco Zaja; 39) Verona,
Cattedra di Ematologia, Policlinico Borgo Roma, G.
Todeschini; 40) Vicenza, Divisione di Ematologia,
Teodoro Chisesi; 41) Vigevano (PV), Divisione di
Medicina Generale, Ospedale Civile, Giuseppe
Attardo Parrinello.
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